金属β-内酰胺酶抑制剂研发的紧迫需求
本文为个人观点文章,指出β-内酰胺类抗生素因耐受性和疗效好而广泛使用,但耐药问题主要由β-内酰胺酶导致;现有β-内酰胺酶抑制剂仅对丝氨酸β-内酰胺酶有效,金属β-内酰胺酶持续传播并对包括碳青霉烯类在内的所有β-内酰胺类耐药。文章总结该领域研究进展、待解决问题,并强调新冠疫情期间金属β-内酰胺酶抑制剂研究的重要性。
要点
- 现有β-内酰胺酶抑制剂仅覆盖丝氨酸β-内酰胺酶,对金属β-内酰胺酶无效。
- 金属β-内酰胺酶持续传播和演化,可导致对包括碳青霉烯类在内的所有β-内酰胺类耐药。
- 重症COVID-19继发细菌性肺炎抗菌药物使用增加,可能加剧耐药问题。
核心结论
- 金属β-内酰胺酶持续传播并对所有β-内酰胺类耐药,现有抑制剂无法覆盖,亟需研发金属β-内酰胺酶抑制剂。
研究设计与样本
- 本文为Personal View(个人观点)文章,总结金属β-内酰胺酶抑制剂研究领域的主要进展与挑战。
主要发现
- 现有β-内酰胺酶抑制剂仅对丝氨酸β-内酰胺酶有效,金属β-内酰胺酶继续传播、演化并导致对包括碳青霉烯类在内的所有β-内酰胺类耐药。
- 重症COVID-19患者继发细菌性肺炎时抗菌药物使用增加,可能加剧抗菌药物耐药问题。
临床怎么用
- 应重视金属β-内酰胺酶抑制剂研发,并在新冠疫情期间关注抗菌药物合理使用以遏制耐药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Due to their superior tolerability and efficacy, β-lactams are the most potent and prescribed class of antibiotics in the clinic. The emergence of resistance to those antibiotics, mainly due to the production of bacterial enzymes called β-lactamases, has been partially solved by the introduction of β-lactamase inhibitors, which restore the activity of otherwise obsolete molecules. This solution is limited because currently available β-lactamase inhibitors only work against serine β-lactamases, whereas metallo-β-lactamases continue to spread, evolve, and confer resistance to all β-lactams, including carbapenems. Furthermore, the increased use of antibiotics to treat secondary bacterial pneumonia in severely sick patients with COVID-19 might exacerbate the problem of antimicrobial resistance. In this Personal View, we summarise the main advances accomplished in this area of research, emphasise the main challenges that need to be solved, and the importance of research on inhibitors for metallo-B-lactamases amidst the current pandemic.
引用
- Mojica MF, Rossi MA, Vila AJ, et al. The urgent need for metallo-β-lactamase inhibitors: an unattended global threat. Lancet Infect Dis. 2021. PMID: 34246322. doi:10.1016/S1473-3099(20)30868-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。